Casey Kopczynski - Aerie Pharmaceuticals Insider

Aerie Pharmaceuticals Inc -- Germany Stock  

EUR 54.33  0.47  0.87%

Co-Founder, Chief Scientific Officer

Dr. Casey C. Kopczynski, Ph.D., is Chief Scientific Officer and CoFounder at Aerie Pharmaceuticals, Inc. From 2002 to 2005, he was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. He was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004, a company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002
Age: 54  Founder Since 2005  Ph.D    
Kopczynski received his PhD in Molecular, Cellular and Developmental Biology from Indiana University and was a Jane Coffin Childs Research Fellow at the University of California, Berkeley.

Management Efficiency

The company has return on total asset (ROA) of (29.43) % which means that it has lost $29.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (128.08) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 123.69 M in total debt with debt to equity ratio (D/E) of 66.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aerie Pharmaceuticals Inc has Current Ratio of 22.0 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Aerie Pharmaceuticals Inc (0P0) is traded on Frankfurt Stock Exchange in Germany. and employs 13 people.

Did you try this?

Run World Markets Correlation Now
   

World Markets Correlation

Find global opportunities by holding instruments from different markets
Hide  View All  Next  Launch World Markets Correlation
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Aerie Pharmaceuticals Inc to your portfolio

Top Management

Aerie Pharmaceuticals Inc Leadership Team
Vicente Anido, Chairman
Julie McHugh, Director, MBA
Murray Goldberg, Executive, MBA
Richard Lewis, Executive
Benjamin McGraw, Director, Ph.D
Casey Kopczynski, Founder, Ph.D
Richard Rubino, CFO
Anand Mehra, Director, Ph.D
Gerald Cagle, Director
Thomas Mitro, President
Richard Croarkin, Director, MBA
Michael Toit, Director
Eric Carlson, President, Ph.D
Tori Arens, President
Geoffrey Duyk, Director, Ph.D
Deanne Melloy, President

Stock Performance

Aerie Pharmaceuticals Performance Indicators